Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720417 · ClinicalTrials.gov registry record · Phase 2
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
A Phase 2 study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04720417 is a Phase 2 study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 13 participants.
The verdict
NCT04720417, a Phase 2 study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This phase II trial studies the effect of combining defactinib and VS-6766 in treating patients with uveal melanoma that has spread to other places in the body (metastatic). The way cells communicate with one another (different cell signaling pathways) are overactive in uveal melanoma tumor cells. Giving defactinib together with VS-6766 may block pathways that are important for the growth of uveal melanoma cells, and may result in shrinkage or stabilization of the cancer and prolonged time to disease progression and survival.
Interventions
- PROCEDURE Biopsy
- DRUG Defactinib Hydrochloride
- DRUG Raf/MEK Inhibitor VS-6766
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-01-26 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04720417
The ClinicalTrials.gov registry entry for NCT04720417 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Biopsy is the first listed.
NCT04720417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04720417 about?
NCT04720417 is a clinical study titled "Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma". This phase II trial studies the effect of combining defactinib and VS-6766 in treating patients with uveal melanoma that has spread to other places in the body (metastatic). The way cells communicate with one another (different cell signaling pathways) are overactive in uveal melanoma tumor cells. G...
What is the current status of trial NCT04720417?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2021-01-26. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT04720417?
The interventions under investigation include: Biopsy (PROCEDURE), Defactinib Hydrochloride (DRUG), Raf/MEK Inhibitor VS-6766 (DRUG).
Who is sponsoring clinical trial NCT04720417?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.